

CURRICULUM VITAE

Masatoshi Tanaka, M.D.

Director, Department of Hepatology and Clinical Research Center, Yokokura Hospital
480-2, Nose, Takada-machi, Miyama, 839-0245, Japan

1979 M.D., Kurume University School of Medicine
1979-84 Resident, Department of Medicine, Kurume University Hospital and Omuta General Hospital
1985-94 Assistant, Department of Medicine, Kurume University Hospital
1995-01 Assistant professor, Department of Medicine, Kurume University Hospital
2001-05 Assistant professor, Hepatology and Gastroenterology, Kurume University Medical Center
2006-12 Associate professor, Hepatology and Gastroenterology, Kurume University Medical Center
2012- Director, Hepatology and Clinical Research Center, Yokokura Hospital

Dr Masatoshi Tanaka graduated Kurume university school of medicine in 1979, and received his PhD degree in Medical Science in 1989. His profession is a diagnosis and treatment of hepatocellular carcinoma (HCC). He started his carrier of percutaneous ethanol injection (PEI) from 1985, intra-arterial embolo-therapy and chemotherapy from 1989, and radiofrequency ablation from 1998. He was a director at the Dept. of Gastroenterology and Hepatology, Kurume University Medical Center, and is now a director of Hepatology and Clinical Research Center, Yokokura hospital since 2012. He is a board member of Liver Cancer Study Group of Japan, Japanese Society of Gastraenterology, Hepatology and Ultrasonics in medicine, and also a director board member of Asian Conference on Tumor Ablation, and organized 2nd ACTA meeting in 2015.

Memberships: Japanese Society of Oncology, Medicine, Gastroenterology, Hepatology, Ultrasonics in medicine, Director board: Asian conference of tumor ablation, and A study group of microwave surgery, Advisory board: Japanese Society of Gastroenterology, Hepatology, Ultrasonics in medicine Editorial board: Japanese Journal of clinical oncology

1. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Yamashita F, Tanaka M, Satomura S, Tanikawa K. *Gastroenterology*. 1996 Oct;111(4):996-1001.
2. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M. *Cancer*. 2002 Aug 1;95(3):588-95.
3. Marginal survival benefit in the treatment of early hepatocellular carcinoma. Midorikawa Y, Takayama T, Shimada K, Nakayama H, Higaki T, Moriguchi M, Nara S, Tsuji S, Tanaka M. *J Hepatol*. 2013 Feb;58(2):306-11.
4. Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma. Tanaka M, Ando E, Simose S, Hori M, Kuraoka K, Ohno M, Yutani S, Harada K, Sata M. *Hepatol Res*. 2014 Feb;44(2):194-200